Biogen Inc reported a better-than-expected quarterly profit on Tuesday and raised its forecast for 2018 adjusted earnings, driven by strong demand for its spinal muscular atrophy drug Spinraza, sending its shares up 3 percent.
Source:: Reuters – Business News
